Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

797
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
797
Cancer Vaccines01:30

Cancer Vaccines

595
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
595

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diet-microbiome synergy underlies obesity-associated immunotherapy efficacy.

Nature·2026
Same author

Distinct immune landscapes characterize highly versus minimally invasive brain metastases.

JCI insight·2026
Same author

Cancer ecosystems: A dynamic interplay across scales.

Cell·2026
Same author

Architecture of the neutrophil compartment.

Nature·2025
Same author

Oncogenic driver mutations underlie the spatial tumour immune landscape of non-small cell lung cancer.

Nature communications·2025
Same author

From complexity to consensus: A roadmap for neutrophil classification.

Immunity·2025

Related Experiment Video

Updated: Nov 4, 2025

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.1K

Immunotherapy for Glioblastoma: Current Progress and Challenges.

Miranda W Yu1,2, Daniela F Quail1,2,3

  • 1Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montreal, QC, Canada.

Frontiers in Immunology
|May 31, 2021
PubMed
Summary

Immunotherapy research for glioblastoma, a lethal brain cancer, faces challenges like tumor heterogeneity and an immunosuppressive environment. Ongoing studies explore immune checkpoint inhibitors, myeloid-targeted therapies, vaccines, and CAR immunotherapies to overcome resistance.

Keywords:
brain cancerglioblastomaimmunotherapyresistance to therapytumor microenvironment

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.7K
Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
04:46

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

1.9K

Related Experiment Videos

Last Updated: Nov 4, 2025

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.1K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.7K
Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
04:46

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

1.9K

Area of Science:

  • Neuro-oncology
  • Immunology
  • Cancer Research

Background:

  • Glioblastoma is a highly lethal brain cancer with poor prognosis despite standard treatments (surgery, radiotherapy, chemotherapy).
  • Recent immunotherapy successes in other cancers highlight its potential for glioblastoma.
  • Therapy resistance and the unique central nervous system immune environment pose significant challenges.

Purpose of the Study:

  • To review current immunotherapy candidates for glioblastoma.
  • To discuss mechanisms of resistance to glioblastoma immunotherapy.
  • To provide insights for developing more effective immunotherapeutics.

Main Methods:

  • Review of ongoing immunotherapy clinical trials and preclinical research for glioblastoma.
  • Analysis of biological barriers to immunotherapy efficacy in the brain.
  • Exploration of resistance mechanisms and potential therapeutic strategies.

Main Results:

  • Several immunotherapy approaches are under active investigation, including immune checkpoint inhibitors, myeloid-targeted therapies, vaccines, and chimeric antigen receptor (CAR) T-cell therapies.
  • Tumor heterogeneity, an immunosuppressive tumor microenvironment, and CNS-specific immune interactions are key resistance factors.
  • Understanding these resistance mechanisms is crucial for advancing glioblastoma immunotherapy.

Conclusions:

  • Despite significant challenges, immunotherapy remains a promising avenue for glioblastoma treatment.
  • Overcoming resistance through novel therapeutic strategies and a deeper understanding of tumor immunology is essential.
  • Continued research into diverse immunotherapy modalities holds potential for improving patient outcomes in glioblastoma.